Biggest News Aggregation in the World

Page 4 - Single Agent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Single Agent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Single Agent Today - Breaking & Trending Today

Adjuvant Treatment With Merck's KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial

Published: June 5, 2022

KEYNOTE-716 is the first Phase 3 trial with an anti-PD-1/L1 to significantly improve distant metastasis-free survival (DMFS) and recurrence-free survival (RFS) for these patientsBased on KEYNOTE-716, KEYTRUDA received US FDA approval and a positive EU CHMP opinion for the adjuvant treatment of patients aged 12 and o...

Source: pharmiweb.com

MEI Pharma, Inc.: MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress

Published: May 12, 2022

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical

Source: finanznachrichten.de

MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress

Published: May 12, 2022

12.05.2022 - MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions ... Seite 1

Source: wallstreet-online.de

ASH 2021 | Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses

Published: December 14, 2021

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Source: prnewswire.com

ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response

Published: November 5, 2021